Ardelyx Investors Offered Chance to Lead Securities Fraud Lawsuit
Rosen Law Firm is notifying investors in Ardelyx, Inc. who purchased shares between January 13, 2025, and August 6, 2026, of an opportunity to serve as lead plaintiff in a securities fraud class action.
New York – October 12, 2026 – Rosen Law Firm has informed investors of Ardelyx, Inc. (NASDAQ: ARDX) about an opportunity to potentially lead a class action lawsuit alleging securities fraud.
The law firm is reminding purchasers of Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive, of a critical lead plaintiff deadline of November 16, 2026. A class action has already been filed against the company.
The lawsuit claims that Ardelyx made positive statements to investors while concealing material facts about the company's commercial performance and growth prospects for its products XPHOZAH and IBSRELA. Specifically, the complaint alleges that the company failed to disclose increasing payer-related barriers affecting patient access, more stringent prior authorization requirements, and step-edit requirements that slowed new patient starts and delayed prescription fulfillment.
According to the lawsuit, when these undisclosed details entered the market, investors suffered damages. Rosen Law Firm encourages investors to select counsel with a strong track record. Those wishing to serve as lead plaintiff must file a motion with the court by November 16, 2026. Participation in the class action does not require any upfront out-of-pocket fees for investors, as the firm operates on a contingency fee basis.